{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:16:57Z","timestamp":1788293817318,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40268-018-0256-6","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T07:46:23Z","timestamp":1544773583000},"page":"27-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Suvorexant (Belsomra\u00ae Tablets 10, 15, and 20\u00a0mg): Japanese Drug-Use Results Survey"],"prefix":"10.1007","volume":"19","author":[{"given":"Yuko","family":"Asai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Iwakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"256_CR1","unstructured":"MHLW (Ministry of Health, Labour and Welfare) Comprehensive Research Project on Scientific Research\/Countermeasures Concerning Persons with disabilities \u201cStudy group on clinical guidelines for proper use and dosage decrease\/discontinuation of hypnotics\u201d and The Japanese Society of Sleep Research\/Working group for formulating guidelines on hypnotics use version, Clinical Guidelines for Proper Use and Withdrawal of Hypnotics; 2013 (in Japanese). \n                    http:\/\/www.jssr.jp\/data\/pdf\/suiminyaku-guideline.pdf\n                    \n                  . Accessed 23 Nov 2017."},{"key":"256_CR2","unstructured":"MSD K.K. Belsomra tablets interview form. Revised November 2016. 6th ed. Tokyo: MSD K.K.; 2016 (in Japanese). \n                    http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/170050_1190023F1024_1_007_1F\n                    \n                  . Accessed 28 Nov 2018."},{"issue":"2","key":"256_CR3","first-page":"249","volume":"11","author":"Y Asai","year":"2017","unstructured":"Asai Y, Miyazaki M, Iwakura M, Hara M. The interim report about the drug use\u2014results survey of orexinergic receptor antagonist, Belsomra, in patients with insomnia. Jpn J Sleep Med. 2017;11(2):249\u201363.","journal-title":"Jpn J Sleep Med"},{"key":"256_CR4","unstructured":"MSD K.K. Belsomra tablets package insert. Revised November 2016. 5th ed. Tokyo: MSD K.K.; 2016 (in Japanese). \n                    http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/170050_1190023F1024_1_11.pdf\n                    \n                  . Accessed 28 Nov 2018."},{"key":"256_CR5","unstructured":"Pharmaceuticals and Medical Devices Agency. Belsomra tablets 15\u00a0mg and 20\u00a0mg Review Report. Tokyo: MSD K.K.; 14 Sep 2014 (in Japanese). \n                    http:\/\/www.pmda.go.jp\/drugs\/2014\/P201400117\/170050000_22600AMX01302_A100_4.pdf\n                    \n                  . Accessed 28 Nov 2018."},{"issue":"2","key":"256_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2016","unstructured":"Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in patients with insomnia: Results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136\u201348. \n                    https:\/\/doi.org\/10.1016\/j.biopsych.2014.10.003\n                    \n                  .","journal-title":"Biol Psychiatry"},{"issue":"3","key":"256_CR7","first-page":"395","volume":"9","author":"N Uchimura","year":"2015","unstructured":"Uchimura N, Hisada S, Takahashi K, Tsumori K, Shimamoto T, Herring WJ. Evaluation of efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with insomnia as a primary disease\u2014comparison of Japanese and overall population\/non Japanese multiregional clinical trial III randomized, double-blind, placebo-controlled trial on efficacy. Jpn J Sleep Med. 2015;9(3):395\u2013411.","journal-title":"Jpn J Sleep Med"},{"issue":"3","key":"256_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","volume":"109","author":"H Sun","year":"2015","unstructured":"Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(3):416\u201326. \n                    https:\/\/doi.org\/10.1016\/j.rmed.2014.12.010\n                    \n                  .","journal-title":"Respir Med"},{"issue":"1","key":"256_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","volume":"12","author":"H Sun","year":"2016","unstructured":"Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12(1):9\u201317. \n                    https:\/\/doi.org\/10.5664\/jcsm.5382\n                    \n                  .","journal-title":"J Clin Sleep Med"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0256-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T19:09:26Z","timestamp":1576264166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0256-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]},"assertion":[{"value":"14 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Yuko Asai, Hideki Sano, Makoto Miyazaki, Mika Iwakura, Yoshikazu Maeda, and Mitsuyoshi Hara are employees of MSD K.K., Tokyo, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}